QURE News and Press, uniQure N.V. From 08/08/22

Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning. Investors weren't all that interested in uniQure's financial results. The comp...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

uniQure ( NASDAQ: QURE ) is trading 27% down premarket after the company reported lower-than-expected Q2 revenue. The company also announced that it was postponing the trial of a higher dose of AMT-130 to treat Huntington’s disease  procedures due to re...

uniQure press release ( NASDAQ: QURE ): Q2 GAAP EPS of -$0.84 beats by $0.11 . Revenue of $0.5M (-99.9% Y/Y) misses by $8.71M . As of June 30, 2022, the Company had cash and cash equivalents of $500.5 million. The Company expects that its cash and cash equivale...

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ...

Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...

Gainers: Fujian Blue Hat Interactive Entertainment Technology (BHAT) +323%. F-star Therapeutics (FSTX) +59%. Rain Therapeutics (RAIN) +43%. The9 Limited (NCTY) +36%. Vroom (VRM) +33%. MSP Recovery (MSPR) +23%. uniQure (QURE) +22%. Azure Power Global (AZRE) +22%. Valneva (VALN) +21%. Anebulo P...

After gene-therapy specialist uniQure (NASDAQ: QURE) reported positive interim results from a phase 1/2 clinical trial early Thursday, its stock surged, gaining 18.5% as of 10:54 a.m. ET. That gene therapy, AMT-130, is intended to treat Huntington's disease, and per the latest updat...

uniQure N.V. (NASDAQ:QURE) added more than 15% after the Dutch biotech announced data from a low-dose cohort of its ongoing U.S.-based Phase I/II clinical trial for gene therapy AMT-130 in the treatment of Huntington’s disease. Out of the 10 patients enrolled in the randomize...

Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...